Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 11/20 | 0.36 |
| ▸ | DRD5 | P21918 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 5/20 | 0.35 |
| ▸ | DRD2 | P14416 | 6/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16625841 | 0.93 | DRD1 (0.40) | DRD1DRD5ALDH1A1USP2KCNH2 | |
| SCHEMBL16625842 | 0.89 | KCNH2 (0.39) | DRD1ALDH1A1USP2KCNH2DRD3 | |
| SCHEMBL16627016 | 0.89 | ADRA1A (0.45) | DRD1DRD5ALDH1A1USP2DRD3 | |
| SCHEMBL16625844 | 0.83 | KCNH2 (0.52) | ALDH1A1KCNH2MAPTALOX15 | |
| SCHEMBL16627561 | 0.81 | ADRA1A (0.47) | DRD1DRD5ALDH1A1USP2DRD3 | |
| SCHEMBL16627018 | 0.78 | ADRA1A (0.47) | DRD1DRD5ALDH1A1USP2DRD3 | |
| SCHEMBL16625830 | 0.76 | KCNH2 (0.48) | DRD1ALDH1A1USP2KCNH2DRD2 | |
| SCHEMBL16627558 | 0.74 | KCNH2 (0.53) | DRD1DRD5ALDH1A1KCNH2DRD3 | |
| SCHEMBL16625822 | 0.71 | KCNH2 (0.64) | DRD1ALDH1A1KCNH2DRD2MAPT | |
| SCHEMBL16625802 | 0.71 | USP2 (0.47) | DRD1DRD5ALDH1A1USP2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181237-B2 | Substituted berbines and their synthesis | MALLINCKRODT LLC (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150099772-A1 | SUBSTITUTED BERBINES AND THEIR SYNTHESIS | SUCAMPO PHARMA AMERICAS LLC | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099772-A1 | SUBSTITUTED BERBINES AND THEIR SYNTHESIS | TYMS, NME2, TYMP | DRD1 2936/4885DRD5 3036/4885ALDH1A1 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.